Document:

Transfer, License and Supply Agreement

 Exhibit 10.12 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406. 

Transfer, License and Supply Agreement 
 between 
 Merck Pharma GmbH 

Alsfelder Straße 17, 
 64289 Darmstadt, Germany 
 (“Merck”), 

and 

Nitec Pharma AG 
 Röschenzerstr. 9, 
 4153 Reinach, Switzerland 

(“Nitec AG”) 
 and 
 Nitec GmbH 

Joseph-Meyer-Str. 13-15 
 68167 Mannheim, Germany 
 (“Nitec Germany”) 

Nitec AG and Nitec German are collectively referred to as “Nitec” 

(all Nitec AG, Nitec Germany and Merck are the “Parties” and each of them – as the case may be – a “Party”) 

Preamble 
  

	1.	Whereas, Merck KGaA having its registered office at Frankfürter Str. 250, 64271 Darmstadt, Germany, (“Merck KGaA”) is the parent company of Merck;

  

	2.	 Whereas, Nitec AG and Merck KGaA as of October 1st, 2004 have concluded a Technology Transfer Agreement (“TTA”) under which the rights of Merck's development
activities regarding the medicinal product Prednison Night Time Release for the indication rheumatoid arthritis have been transferred to Nitec AG. Nitec has further developed the Project (as defined in the TTA) and owns any rights relating to the
PRODUCT, as defined; 

  

 1/22 

	3.	Whereas, under the TTA Merck KGaA has been granted by Nitec AG the option to obtain exclusively the distribution and marketing rights pertaining to the PRODUCT in
Germany and Austria and desires to make use of this option in Germany via Merck; 

  

	4.	Whereas, Nitec AG, through Nitec Germany, has applied for the MARKETING AUTHORIZATION for the PRODUCT in Germany with the competent authority thereby becoming a
Marketing Authorization Holder (“MAH”), as defined in § 4 subp. 18 Arzneimittelgesetz (“AMG”); 

  

	5.	Whereas, Nitec AG is willing to cause Nitec Germany to transfer the MARKETING AUTHORIZATION to Merck, if and when the MARKETING AUTHORIZATION has been obtained by Nitec
Germany; 

  

	6.	Whereas, Nitec AG - through Nitec Germany - intends to apply for additional marketing authorizations for products which are — except its names - identical with the
PRODUCT (“Duplicate Authorization”) and whereas, Nitec will not make use of more than one Duplicate in the TERRITORY and only to the extent as provided for in Art. 5.8 of this AGREEMENT; 

 

	7.	Whereas, Nitec AG is the owner of the registered trademark “Lodotra” and whereas, Nitec AG is willing to grant Merck an exclusive licence in the TERRITORY to
use the TRADEMARK; 

  

	8.	Whereas, neither Nitec AG nor Nitec Germany are holder of manufacturing authorizations and whereas, Nitec AG has entrusted third parties with the manufacture of the
PRODUCT. 

 Now, therefore, the Parties agree as follows: 
 Article 1- Definitions 
 As used in this AGREEMENT, the following words and phrases shall
have the following meanings: 
 “AGREEMENT” means this Transfer, License and Supply Agreement between the Parties as set out
and described herein. 
 “ANNUAL MINIMUM SALES” shall mean [...***...] of the TARGET SALES. 

“EX FACTORY PRICE” is the list price of the PRODUCT without discounts by Merck to each independent customer. 

“LAUNCH” refers to the day on which the PRODUCT is brought onto the market in the TERRITORY. 

 

 ***Confidential Treatment Requested 

2/22 

 “MARKETING AUTHORIZATION” shall mean the authorization and related documents granted by the
German competent authority, the Bundesinstitut für Arzneimittel and Medizinprodukte (“BfArM”) for the marketing, distribution and sale of the PRODUCT in the TERRITORY. 
 “PRODUCTION COSTS” are all costs incurred by Nitec in the complete provision of PRODUCT to one of Merck’s supply depots. 
 “PRODUCT” shall mean the medicinal product in its finished form ready for sale in the TERRITORY and in accordance with the SPECIFICATIONS described in Appendix 1 attached hereto.

 “SPECIFICATIONS” means the specifications for PRODUCT (including shelf life), attached hereto, incorporated in and made part
of this AGREEMENT as Appendix 1. 
 “TARGET SALES” shall mean the target sales as set forth in Appendix 2, such sales of
the PRODUCT in the TERRITORY by Merck shall be those reported by IMS or by any other source mutually agreed by the Parties offering a service similar to the one currently offered by IMS. At the date of signature of this AGREEMENT Appendix 2
is a preliminary estimation and the definite number will be calculated in accordance with the actual daily therapy costs. An example calculation is incorporated in Appendix 2. 
 “TERM” shall mean the term set forth in Section 16.1. 

“TERRITORY” shall mean the territory of Germany. 
 “TRADEMARK” shall mean “Lodotra”, Swiss Registration No. 535 303. If this TRADEMARK should be rejected by the BfArM in connection with the application for the MARKETING
AUTHORIZATION for PRODUCT filed by Nitec Germany, Nitec shall use an alternative trademark for the PRODUCT, such alternative trademark to become automatically the TRADEMARK. 
 Article 2- Transfer and License 
  

	2.1	Subject to the terms and conditions of this AGREEMENT, Nitec AG hereby undertakes to transfer to Merck — through Nitec Germany — the MARKETING AUTHORIZATION
for the PRODUCT and hereby grants to Merck an exclusive licence to use the TRADEMARK for the PRODUCT during the TERM of this AGREEMENT in the TERRITORY. The term exclusive license shall mean for the purpose of this AGREEMENT that Nitec shall not
grant a license to use the TRADEMARK in the TERRITORY to any other party. 

  

	2.2	Merck is not entitled to transfer, assign or sublicense its granted rights pursuant to Article 2.1 without the prior written consent of Nitec AG.

  

	2.3	 Merck shall be considered as an independent contractor and shall not be considered a partner, agent or representative of Nitec. As such, no Party shall

  

 3/22 

	 	 
have the authority to create or assume any obligation in the name of the other Party nor to bind the other Party in any manner whatsoever. 

Article 3- Marketing Authorization and Trademark 
  

	3.1	When the MARKETING AUTHORIZATION in the TERRITORY has been obtained by Nitec Germany, Nitec AG shall cause Nitec Germany to transfer to Merck for the duration of this
AGREEMENT the MARKETING AUTHORIZATION and shall license the TRADEMARK to Merck for Merck’s exclusive use hereof, in each case limited to the TERRITORY. 

 

	3.2	Merck shall not market, sell and distribute the PRODUCT in the TERRITORY under any other name than the TRADEMARK. 

 

	3.3	At Merck’s sole expense, Merck agrees to (a) maintain the transferred MARKETING AUTHORIZATION in the TERRITORY, (b) diligently promote, market, sell and
distribute the PRODUCT in the TERRITORY and (c) promptly assign back to Nitec Germany or any other party, designated by Nitec Germany, the MARKETING AUTHORIZATION and relating rights in the TERRITORY upon termination of this AGREEMENT.

  

	3.4	If at any time during the TERM of this AGREEMENT either Party shall become aware of any infringement or threatened infringement by a third party of the TRADEMARK or any
other right belonging to one of the Parties pursuant to this AGREEMENT, the Party having the knowledge thereof shall give prompt notice to the other Party, and the Parties shall consult as to the action to be taken. Any such action shall be taken by
Nitec AG at the cost of Nitec AG. Merck may, at its own cost, assist Nitec AG holding the TRADEMARK infringed upon or threatened to be infringed upon in taking legal action against such infringement or threatened infringement.

  

	3.5	Upon termination of this AGREEMENT, Merck’s right to use the TRADEMARK ceases. 

 Article 4- Maintenance of Marketing Authorization, Launch 
  

	4.1	Merck shall make all declarations and filings to maintain the MARKETING AUTHORIZATION. 

 

	4.2	The PRODUCT, subject to Nitec AG’s ability to deliver the PRODUCT, shall be launched within [...***...] after the MARKETING AUTHORIZATION has been
transferred by Nitec Germany to Merck. 

  

	4.3	 If LAUNCH of the PRODUCT shall be delayed due to reasons beyond reasonable control of Merck and Nitec. Parties will share those resulting losses
[...***...] which are caused 

  

 ***Confidential Treatment Requested 

4/22 

	 	 
by a reduction of the shelf-life to less than [...***...]. Sharing of such losses shall lead to reimbursement of payments already made by Merck for purchase of the PRODUCT whose shelf-life
is so reduced. 

 Article 5- Marketing and Sales Activities 

 

	5.1	Merck will perform all industry-standard and customary pre-marketing activities [...***...] prior to the envisaged LAUNCH of the PRODUCT.

  

	5.2	Merck will use its commercially reasonable efforts to market the PRODUCTS comparable to the common practice of the industry for products of a comparable market size.

 In any event, but subject to Section 4.2, Merck will launch the PRODUCT in the TERRITORY no later than
[...***...] following transfer of the MARKETING AUTHORIZATION to Merck by Nitec Germany hereunder, price approval and other official approvals, to the extent that these approvals are a condition for so launching PRODUCT. 

 

	5.3	Merck agrees that all material used in connection with the promotion and distribution of the PRODUCT shall comply with the applicable law and any information contained
in such material shall be consistent with the MARKETING AUTHORIZATION. 

 The marketing plan of the PRODUCT for the
following year shall be presented and provided to Nitec AG during the fourth quarter of each year. 
  

	5.4	No written or printed material relating to the PRODUCT shall be used by Merck without Nitec AG’s prior written consent. Any information on written or printed
materials provided to Nitec shall be subject to Article 12. 

 If within [...***...] business days after
receipt of such material, Nitec AG or Nitec Germany does not inform Merck, that it objects to the presented materials or, if Nitec AG or Nitec Germany, in case of objections, within [...***...] more working days do not inform Merck in writing
of the reasons for the objection, such material shall be considered approved by Nitec AG. The consent of Nitec AG may not be unreasonably withheld. 
 Merck shall not initiate and/or conduct any Phase III/IV clinical studies for the PRODUCT without Nitec AG’s prior written consent. 

 

	5.5	Each Party will provide the other free of charge with the results of its market research activities for the PRODUCT in the TERRITORY. Additionally, Nitec AG shall
provide Merck with all results obtained by studies conducted by or on behalf of Nitec AG in relation to the indication rheumatoid arthritis. 

  

	5.6	 Within [...***...] days following each calendar quarter, Merck shall send to Nitec a copy of the Merck’s internal sales report covering the
preceding quarter. 

  

 ***Confidential Treatment Requested 

5/22 

	 	 
Each such quarterly sales report shall show the total distribution of the PRODUCT (sales) in units and values for each dosage form. 

The sales report shall include separate figures for wholesaler and hospital supply. 

During the twelve (12) month period starting with the first commercial introduction Merck will provide Nitec AG monthly sales (in
units and values). 
 Each Party shall inform the other Party of any proposed and/or approved regulations and/or laws which could
influence the sales of the PRODUCT 
  

	5.7	Should Merck not reach TARGET SALES or, respectively, the ANNUAL MINIMUM SALES as agreed upon same shall not be regarded as a breach of this AGREEMENT. Upon such
occurrence representatives of both Parties shall propose measures to reach the TARGET SALES. The evaluation of achieved versus TARGET SALES will be performed every [...***...] months. 

 

	5.8	Should ANNUAL MINIMUM SALES not be reached in any [...***...] (the first such period to commence upon LAUNCH) during the TERM due to reasons not attributable to
Nitec and/or the third party manufacturer, and same shall not be remedied within [...***...] after respective notice by Nitec to Merck, Nitec’s exclusive remedy shall be the right to make use of the Duplicate Authorization, as defined in
No. 6 of the Preamble effective as of the end of the [...***...] period and to introduce or to have introduced a product in the TERRITORY under such duplicate authorization. In such a case, the continuation of this AGREEMENT shall not be
subject to any ANNUAL MINIMUM SALES. 

  

	5.9	For the purposes of Art. 5.6 and 5.7, the sales of the PRODUCT in the TERRITORY by Merck shall be those reported by IMS or by any other source mutually agreed by the
Parties offering a service similar to the one currently offered by IMS. 

 Article 6- Ex factory Price 

 

	6.1	Merck shall draw up a statistically valid pricing study of a type that is customary in this market at its own cost in due time based on the clinical Phase Ill study
results and make same available to Nitec free of charge. 

  

	6.2	The EX FACTORY PRICES will be discussed by the Parties sufficiently in advance of the LAUNCH based on the above described pricing study and fürther relevant
criteria, it being understood that the prices shall be set by Merck. The EX FACTORY PRICE will be discussed by the Parties upon either Party’s written request at any time in light of the then current market situation without limiting
Merck’s right to set the price. 

  

	6.3	 In case of reductions of the price imposed by the Health Insurance Institutions and to be paid by the ultimate customer or to be reimbursed by the
Health 

  

 ***Confidential Treatment Requested 

6/22 

	 	 
Insurance in accordance with the Sozialgesetzbuch Tell V (SGB V) or the possibility of such price reductions Merck will use its reasonable best efforts to convince the Institut für
QuaRät and Wirtschaftlichkeit im Gesundheitswesen (IQWIG) (§ 139a SGBV) (or any other similar institution) about the additional benefit of the PRODUCT compared to standard prednisone tablets to avoid any reference price (Festbetrag) or
other price reduction. 

 Article 7- Supply and Orders 

 

	7.1	Merck agrees to exclusively purchase from Nitec AG, all of Merck’s requirements of the PRODUCT. Nitec AG hereby agrees to use commercially reasonable efforts to
meet Merck’s requirements for the PRODUCT. Nitec AG is entitled to have the PRODUCT in its name directly delivered by the third party manufacturer under contract to Merck. For the avoidance of doubt, Nitec AG remains liable for the delivery of
the PRODUCT. 

  

	7.2	The minimum purchase order, irrespective of the dosage for the tablets, shall be [...***...], divided into [...***...]. Purchase orders in excess of such
[...***...] shall be the multiple of [...***...] tablets. Merck and Merck Gesellschaft mbH, Austria may internally combine purchase orders for PRODUCT to reach the amounts mentioned in this section 7.2. 

 

	7.3	The PRODUCT will be delivered in accordance with Appendix 1. 

  

	7.4	The Parties shall agree upon the packaging design which shall comply with the legal requirements in the TERRITORY. 

 

	7.5	At the end of each calendar quarter Merck shall provide Nitec AG with a written non-binding rolling forecast of Merck’s requirements of the PRODUCT, per month, for
the next 18 months. The first rolling forecast shall be provided to Nitec AG at the same time as placement of first purchase order. Orders shall also be placed at the end of each calendar quarter. 

 

	7.6	At least [...***...] months in advance of the requested delivery date of the PRODUCT, Merck shall submit to Nitec AG a written purchase order for the desired
quantities of the PRODUCTS. Such purchase order shall be firm and binding upon Merck when accepted by Nitec AG, Nitec shall not be entitled to decline any orders which are up to [...***...] of the respective forecast and shall use its
reasonable commercial efforts to fulfill orders above [...***...]. Each order placed by Merck will bear the exact quantity (including pack-size and dose strengths) ordered in accordance with section 7.2, the delivery date and the address at
which the PRODUCT must be sent. When shorter delivery times could be achieved, Nitec AG shall promptly inform Merck hereof. 

  

	7.7	 Merck shall maintain a minimum inventory level of the PRODUCT corresponding to at least [...***...] sales calculated on the basis of the

  

 ***Confidential Treatment Requested 

7/22 

	 	 
actual sales forecast or otherwise agreed upon by the Parties provided that Nitec AG supplies to Merck the PRODUCT in accordance with this AGREEMENT. 

Article 8- QUALITY of the PRODUCT 
  

	8.1	The PRODUCT to be delivered by a third party manufacturer in the name of Nitec AG to Merck hereunder shall be finished and released goods, be free from defects, conform
to the analysis certificates which are delivered with the PRODUCT and will be in accordance with the SPECIFICATIONS for the PRODUCT. Nitec assures that the third party manufacturer at any time complies with the requirements of the Betriebsverordnung
für pharmazeutische Unternehmer (PharmBetrV) and of the EC-Guideline of Good Manufacturing Practice for medicinal products, Part I: Basic requirements for medicinal products (GMP) and that the quality of the PRODUCT complies with the MARKETING
AUTHORIZATION dossier. 

  

	8.2	The provisions contained in § 377 Handelsgesetzbuch shall not be applicable. Merck shall, however, inspect PRODUCT delivered within five (5) working days of
receiving delivery and shall inform the party effecting the delivery (with a copy to Nitec AG) within such five day period of any shortages, defects or obvious off specification characteristics. Other defects have to be reported promptly upon
discovery, but in no event later than five (5) working days after such discovery. 

 Article 9- Supply Price and Terms of
Payment 
  

	9.1	The prices to be paid by Merck to Nitec AG for the PRODUCT (including samples) shall be at the higher of (i) [...***...] of the EX FACTORY PRICES or
(ii) PRODUCTION COSTS plus [...***...] of the EX FACTORY PRICES. In the event that the PRODUCT becomes subject to mandatory reimbursements imposed by the authorities (e.g. Zwangsrabatte), NITEC AG and Merck shall share the economic
burden of such mandatory reimbursements as follows: 

  

	 	•	 	 In the event that Merck has paid NITEC AG according to lit. (i) above Nitec AG shall re-imburse to Merck [...***...] of the reduction
amounts actually paid by Merck to the authorities. 

  

	 	•	 	 In the event that Merck has paid NITEC AG according to lit. (ii) above Nitec AG shall re-imburse to Merck the share of the reduction amounts
actually paid by Merck to the authorities which is equal to PRODUCTION COSTS plus [...***...] of the EX FACTORY PRICE divided by the EX FACTORY PRICE. Reimbursements by NITEC AG shall be limited to [...***...] of the EX FACTORY PRICES.

  

 ***Confidential Treatment Requested 

8/22 

	9.2	Invoices shall be payable without discount within [...***...] days from the date of invoice. 

Article 10- General Obligations of Merck 

Merck shall have the following general obligations: 
  

	10.1	Merck shall comply with all applicable laws and regulations, especially with the AMG, with the Heilmittelwerbegesetz (“HWG”), with the PharmBetrV and with the
Betriebsverordnung für Arzneimittelgroßhandelsbetriebe. 

  

	10.2	Merck will use its reasonable best efforts to further the marketing, selling and distribution of the PRODUCT in the TERRITORY in accordance with the terms of this
AGREEMENT and to obtain the relevant authorizations, if any; 

  

	10.3	Merck shall promptly respond to all inquiries from customers, including complaints, process all orders, and effect all dispatches of the PRODUCT.

  

	10.4	Merck shall promptly provide Nitec AG with written reports of any importation or sale of the PRODUCT in the TERRITORY of which Merck has knowledge from any source other
than Nitec AG, as well as with any other information related to the PRODUCT, which Nitec AG may reasonably request in order to be updated on the market conditions in the TERRITORY 

 

	10.5	Merck shall inform Nitec AG of any requirements for changes of the packaging, labelling, Patient information in the TERRITORY. 

 

	10.6	The Parties agree to establish a joint product committee to meet regularly, at least every four (4) months, to evaluate marketing and sales performance as related
to annual sales and purchase plans delivered to Nitec AG according to Article 7.5 of this AGREEMENT. 

 Article 11- General
Obligations of Nitec 
 Nitec shall have the following obligations during the TERM of this AGREEMENT: 

 

	11.1	Nitec AG shall secure that Nitec Germany files a variation notice with the BfArM relating to the transfer of the MARKETING AUTHORIZATION to Merck in accordance with
§ 29 subp. 1 AMG and informs Merck of that notification by copy. 

  

	11.2	Nitec AG will supply Merck with all presently available or future documents and information concerning the PRODUCT as far as such documents and information are needed
by Merck for the fulfillment of its obligations under this AGREEMENT. 

  

 ***Confidential Treatment Requested 

9/22 

	11.3	Nitec AG will provide Merck with examples for technical literature, promotional and advertising material, etc. as both Parties consider to be reasonably sufficient to
promote sales of the PRODUCT in the TERRITORY and as far as available within Nitec. 

 Article 12- Secrecy 

 

	12.1	The Parties agree and undertake that they will keep secret all disclosures by the other Party, written or oral, made either before or during the TERM of this AGREEMENT.
The receiving Party will not without the prior written consent of the other Party use, except as expressly contemplated by this AGREEMENT, or disclose to any third party any information relating to the PRODUCTS learned by or disclosed to the other
Party pursuant to or in connection with this AGREEMENT (together “Information”). 

  

	12.2	The confidentiality obligations hereinabove mentioned shall not apply to: 

  

	 	a)	Information in the public domain 

  

	 	b)	Information known by the receiving Party before the date hereof and which the receiving Party can conclusively prove that it was not obtained, directly or indirectly
from the disclosing Party. 

  

	 	c)	Information legally obtained by the receiving Party after the date hereof from a third party which has it in its possession legally. 

 

	 	d)	Information which the receiving Party is legally obliged to reveal to authorities or clients. 

 

	12.3	The provisions of this Article shall remain in force during the period of this AGREEMENT and for a further period of two (2) years after the termination thereof.

 Article 13- Responsibility, Liability and Indemnification 

 

	13.1	Merck shall be responsible for fulfilling and securing all requirements, regulations, licenses and permissions which are necessary to distribute, sell and market the
PRODUCT in finished form in the TERRITORY. 

  

	13.2	Nitec AG indemnifies Merck from all damages arising out of any negligent or willful breach of its obligations according to this AGREEMENT or arising out of the use by
Merck in the performance of this AGREEMENT of information or data disclosed by Nitec pursuant to this AGREEMENT. 

Subject to the limitation in Section 13.4, Nitec AG will indemnify Merck and its Affiliates (and their respective officers, directors
and employees) from and 
  

 10/22 

 
against any and all damages sustained or incurred by any of them because of any third party personal injury or wrongful death claim to the extent such damages arise out of: (i) the
negligence or wilful misconduct of Nitec or its Affiliates (or their respective officers, directors or employees), (ii) any breach by Nitec of any provision of this AGREEMENT, including without limitation any PRODUCT warranty made by Nitec in
this AGREEMENT; or (iii) any latent defect in PRODUCT. Nitec AG will indemnify and hold Merck and its Affiliates (and their respective officers, directors and employees) harmless from and against any and all damages sustained or incurred by any
of them to the extent that they arise out of any third party claim of violation or infringement of any proprietary right of said third party relating to Nitec’s proprietary information used in the manufacture of PRODUCT. Notwithstanding the
foregoing, Nitec shall have no such indemnity obligation to the extent such third party claims are based on, arise out of, or are caused by, the negligence or wilful misconduct of Merck or its Affiliates (or their respective officers, directors or
employees). 
 Upon filing of any such claim, Merck shall immediately notify Nitec AG in writing and shall offer Nitec AG to
control the defense against any such claim. If Nitec AG declines the offer to so control the defense, then Merck shall keep Nitec AG fully informed at all times of its own measures to defend such claim and shall allow Nitec AG to comment on any
material measures prior to Merck taking such measures in the course of the defense. Any settlement or acknowledgement of such claim or any waiver of a defense by Merck shall require the prior written consent of Nitec AG. Failure to obtain such
consent shall exclude Merck’s right to recover damages under this section 14 for the respective claim. 
  

	13.3	Merck, subject to the limitations in Section 13.4, indemnifies Nitec from all damages arising out of the breach of any obligation of Merck according to this
AGREEMENT. Merck will indemnify Nitec for all damage resulting from any third party claims against Nitec, which arise from the distribution, marketing and sale of the PRODUCTS, if not attributable to Nitec as per clause 13.2. Upon filing of any such
claim, Nitec shall immediately notify Merck and the third full paragraph of section 13.2 shall apply mutatis mutandis. 

  

	13.4	Subject to mandatory law, neither party shall be liable or responsible for any exemplary, punitive, special, indirect, consequential or incidental damages of any kind
whether based on contract, tort (including negligence), strict liability, or any other theory or form of action even if a party has been advised of the possibility thereof. 

 Article 14- Exchange of Information and Pharmacovigilance 
  

	14.1	 The Parties shall keep each other informed on all matters related to the PRODUCT and on any information received from any source concerning

  

 11/22 

	 	 
adverse drug reactions coming to either Party’s knowledge with regard to the PRODUCT. 

  

	14.2	Merck is responsible for fulfilling the documentation and reporting obligations in accordance with the legal requirements. If both Parties are marketing authorisation
holders in the TERRITORY they will agree on appropriate measurements in order to avoid double reporting to competent authorities. Independently of any national reporting requirements, the Parties hereto shall in relation to the PRODUCT report to
each other all serious adverse events from clinical trials with a reasonable suspicion of causal relationship to the administered PRODUCT and all serious spontaneously reported suspected adverse drug reactions. 

 

	14.3	In any case where a change in the risk-benefit-ratio becomes evident or risk minimizing steps due to adverse drug reactions seem to be necessary (e.g. change of the
label, PRODUCT information, special information/warnings to the medical profession, patients, authorities or recall of the PRODUCT), the Parties hereto will inform each other without delay and harmonise further measures as appropriate. Such exchange
of information is realised through direct contacts between the appropriately qualified persons responsible for pharmacovigilance (Stufenplanbeauftragte) of each party pursuant to § 63 a AMG. Therefore, both Parties undertake to inform each
other on any change in the responsible persons, the address, telephone and fax-numbers. 

  

	14.4	Any information on drug safety issues as pointed out above shall be fürnished by a Party to the other Party in the English language. 

 

	14.5	Merck will be responsible for preparing the periodic safety update reports in accordance with the law and shall provide copies of same to Nitec.

  

	14.6	Nitec agrees that the obligations contained in this Article 14 may be performed by Merck KGaA. Fürther details will be set forth in the Safety Data Exchange
AGREEMENT between Nitec AG and Merck KGaA to be concluded in due course. Merck agrees that the obligations of Nitec may be performed by a third party selected by Nitec. 

 Article 15- Non Competition 
 Within the first three (3) years following the LAUNCH of the
PRODUCT, Merck shall refrain from launching oral glucocorticoids in the indication “rheumatoid arthritis”. 

  

***Confidential Treatment Requested 
 12/22 

 Article 16- Term and Termination 

 

	16.1	Term 

 This AGREEMENT
shall take effect as of the signature by all parties and, unless otherwise terminated as provided in this AGREEMENT, shall remain in full force and effect for a period of 10 (ten) years as of the LAUNCH. 

Thereafter, the AGREEMENT will be automatically renewed for successive periods of [...***...] until terminated by either Party
giving [...***...] months prior written notice to the other Party. 
  

	16.2	Termination 

Notwithstanding other rights to terminate this AGREEMENT pursuant to Art. 16.1, this AGREEMENT may be terminated with immediate effect in
accordance with the following provisions: 
  

	 	a)	Either Party may terminate this AGREEMENT at any time by giving notice in writing to the other Party, which notice shall be effective upon dispatch, should the other
Party file a petition of any type as to its bankruptcy, be declared a bankrupt, become insolvent, make an assignment for the benefit of creditors, go into liquidation or receivership; 

 

	 	b)	Either Party may terminate this AGREEMENT by giving notice in writing to the other Party should an event of force majeure as provided in Article 17.4 continue
for more than [...***...] months; 

  

	 	c)	Either Party may terminate this AGREEMENT by giving notice in writing to the other Party stating that this AGREEMENT might terminate under this Article 16.2., if the
other Party (i) commits a material breach of any condition herein contained, and does not within [...***...] days from receipt of written notice by the other Party of such breach remedy the same, if capable of remedy, or offer full
compensation therefore; or (ii) if the other Party repetitiously commits a breach of any condition contained herein, and the aggregate of such repetitious breach represents a material breach of this AGREEMENT. 

 

	16.3	Rights and Obligations on Expiration and Termination 

In the event of termination or expiration of this AGREEMENT for any reason, the Parties shall have the following rights and obligations:

  

	 	a)	Merck shall without undue delay transfer the MARKETING AUTHORIZATION for the PRODUCT to Nitec Germany or to a third party designated by Nitec Germany.

  

	 	b)	All of Merck’s rights under or related to the TRADEMARK automatically end upon termination of this AGREEMENT. 

  

***Confidential Treatment Requested 
 13/22 

 Termination of this AGREEMENT shall not release either Party from the obligation to deliver
or to make payment of all amounts then or thereafter due and payable; 
  

	16.4	Both Parties’ obligations pursuant to secrecy in Article 12 shall survive termination of this AGREEMENT; 

 

	16.5	In case of termination or expiration of this AGREEMENT, Merck will discontinue to distribute, to market and to sell the PRODUCT, if not stated otherwise in this
AGREEMENT. 

  

	16.6	In the event of termination of this AGREEMENT, Nitec AG may repurchase stocks of PRODUCT held by Merck at the prices Merck has bought the PRODUCT from Nitec AG, if
Nitec AG so chooses. Otherwise Merck is entitled to distribute the remaining stocks within [...***...] within the TERRITORY. All stocks remaining after this period of [...***...], including but not limited to all PRODUCT which might be
returned thereafter, have to be destroyed at Merck’ responsibility and costs, a proof of which shall be submitted to Nitec AG. 

 Article 17- Miscellaneous 
  

	17.1	Notices. 

 All notices,
demands and communications required to be made under this AGREEMENT shall be in writing and delivered personally or sent by telefax and confirmed by airmail letter to the addresses shown above. Notice shall be deemed delivered on the date of
delivery when delivered personally or on the third business day after the day on which they were sent by telefax or fourteen (14) days after being mailed by airmail letter, which provides for a signed receipt upon delivery. 

 

	17.2	Headings. 

 It is agreed
by the Parties hereto, that the headings of the clauses herein have been included for convenience only and do not form any part of the AGREEMENT. 
  

	17.3	Severability. 

 In the
event that any provision of this AGREEMENT is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any law of any relevant jurisdiction, the Parties shall replace any Article or part of an Article
found to be invalid or unenforceable by alternative provisions which shall be as similar as possible in their conditions with regard to their spirit and commercial effect. The validity of the remaining provisions shall not be affected. 

 

 ***Confidential Treatment Requested 

14/22 

	17.4	Force Majeure. 

 In
the event that the performance of this AGREEMENT or of any obligation hereunder, other than payment of money as herein provided, by either Party is prevented, restricted or interfered with by reasons of any cause not within the control of the
respective Party, and which could not by reasonable diligence have been avoided by such Party, the Party so effected, upon giving prompt notice to the other Party as to the nature and probable duration of such event, shall be excused from such
performance to the extent and for the duration of such prevention, restriction or interference, provided that the Party so affected shall use its best efforts to avoid or remove such cause of non-performance and shall fulfil and continue performance
hereunder with the utmost dispatch whenever and to the extent such cause or causes are removed. 
  

	17.5	Assignment. 

 Merck and
Nitec may assign its rights and obligations under this AGREEMENT, in whole or in part, to any AFFILIATE upon prior written consent from Nitec or Merck respectively, which consent shall not be unreasonably withheld or delayed, provided that in each
case the transferring party agrees to be fully responsible for the receiving AFFILIATE'S performance of this AGREEMENT. 
  

	17.6	Hardship. 

 Should the
effects of this AGREEMENT resulting from future unforeseen events and developments lead to an unjust hardship for either Party and which hardship does not correspond with the intention of the Parties in good faith, the Parties shall without delay
enter into negotiations to see in what way the conditions of the AGREEMENT can be made to suit altered circumstances. 
  

	17.7	Waiver. 

 If any Party
should at any time refrain from enforcing its rights arising from a breach or default by the other Party of any of the provisions of this AGREEMENT, such waiver shall not be construed as a continuing waiver regarding that breach or default or other
breaches or defaults of the same or other provisions of this AGREEMENT. 
  

	17.8	Conflicting Agreements. 

 In the event any provisions contained in the TTA shall conflict with the provisions contained in this AGREEMENT, this AGREEMENT shall prevail. 

 

	17.9	Written Form. 

 No
waiver, alteration or modification of any of the provisions hereof shall be binding unless made in writing and signed by duly authorized officers of the Parties. Any waiver of this written form requirement shall be in writing. 

 

 15/22 

 Article 18- Governing Law 
 This AGREEMENT shall be governed by and interpreted in accordance with the laws of Germany without its provisions on the conflict of laws and without the UN Convention on the international Sale of Goods
(CISG) and the rules incorporating this convention into German law. 
  

					
	Reinach, den 19.12.2006	 		 	Darmstadt, den 21.12.2006
			
	Nitec Pharma AG	 		 	Merck Pharma GmbH
			
	 /s/ Dr. Hubertus Ludwig
	 		 	 /s/ Rosemarie Schiemer

	(Dr. Hubertus Ludwig)	 		 	(Rosemarie Schiemer)
			
	Mannhein, den 19.12.06	 		 	
			
	Nitec Pharma GmbH	 		 	
			
	 /s/ Jochen Mattis
	 		 	
	(Jochen Mattis)	 		 	

 Appendix 1    Specifications and Supply Conditions 

Appendix 2    Target Sales 

  
 16/22

 Transfer, License and Supply Agreement 

Appendix 1 
 (1)
Composition of the medicinal products 
 Lodotra 1mg 

 

									
	 Component
	 	 Per Tablet Formula
	 	 Percentage Formula
	 	 Function
	 	 Quality Standard

					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
			
	 [...***...]
	 	[...***...]	 	

  

***Confidential Treatment Requested 
 17/22 

 Lodotra 2mg 
  

									
	 Component
	 	 Per Tablet Formula
	 	 Percentage Formula
	 	 Formula
	 	 Quality Standard

					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
			
	 [...***...]
	 	[...***...]	 	

  

***Confidential Treatment Requested 
 18/22 

 Lodotra 5mg 
  

									
	 Component
	 	 Per Tablet Formula
	 	 Percentage Formula
	 	 Formula
	 	 Quality Standard

					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
	 [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
			
	 [...***...]
	 	[...***...]	 	

 [...***...] 

  

***Confidential Treatment Requested 
 19/22 

 [...***...] 
  

							
	 Test
	 	 Specifications on
release

				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 [...***...]
	 	[...***...]	 		 	
				
	 – [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]
				
	 – [...***...]
	 	[...***...]	 		 	

  

***Confidential Treatment Requested 
 20/22 

 [...***...] 
 [...***...] 
 [...***...] 
 [...***...] 
 [...***...] 
 [...***...] 
 [...***...] 
 [...***...] 
  

 ***Confidential Treatment Requested 

21/22 

 [...***...] 
 Appendix 2 
 [...***...] 

[...***...] 

[...***...] 
 [...***...]

 [...***...] 
  

			
	 [...***...]
	  	 [...***...]

		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]
		
	 [...***...]
	  	[...***...]

 [...***...] 

[...***...] 

[...***...] 
  

 ***Confidential Treatment Requested 

22/22Letter Agreement

 Exhibit 10.32 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406. 

 

 

 CONFIDENTIAL 
 March 2, 2011 
 Via email 
 The General Manager 
 Mundipharma International Corporation Limited, 

Mundipharma Medical Company, 
 Mundipharma House,
14 Par-la-Ville Road 
 P.O. Box HM 232, Hamilton HM JX, 
 Bermuda 
 Re: Exclusive Distribution Agreement, dated March 24, 2009 (the “EDA”),
by and between Horizon Pharma AG (previously Nitec Pharma AG) (“Horizon”) and Mundipharma International Corporation Limited (“Mundipharma”); the Manufacturing and Supply Agreement dated March 24, 2009 (the “MSA”),
by and between Horizon and Mundipharma Medical Company (“MMCo”); and the Assignment Agreement to be entered into by Horizon, Horizon Pharma GmbH, Merck Serono GmbH (“Merck”), Mundipharma and MMCo for the transfer of rights and
obligations relating to the Product in Germany (the “Assignment Agreement”). 
 Dear Sir, 

As we have discussed, in order to clarify certain of the parties’ rights and obligations under the EDA, MSA and Assignment Agreement, and to
facilitate the funding of a study of Product for the treatment of Polymyalgia Rheumatica (“PMR”) to be conducted by, or on behalf of, Mundipharma and Horizon pursuant to the EDA and this letter agreement, Horizon, Horizon GmbH, Mundipharma
and MMCo, intending to be legally bound, agree as set forth below. Capitalized terms used but not otherwise defined in this letter agreement shall have the meanings provided in the EDA. For clarification, Horizon shall have no obligation to fund or
contribute to the funding of any study of Product for the treatment of PMR except as expressly set forth in this letter agreement. 
 (a) The following milestone event and corresponding milestone payment is hereby eliminated from Schedule 5 of the EDA: 
  

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	 	[...***...]	  

  

***Confidential Treatment Requested 
 Horizon Pharma AG, Kagenstrasse 17, CH-4153 Reinach, Switzerland 

 

 

  

 (b) Horizon agrees to provide Mundipharma with a credit in the
amount of [...***...] that can be applied in full to the next, consecutive milestone payment(s) that become due to Horizon under the EDA, provided that such credit shall not be applied to the milestone
payments discussed in subsection (c) below. Horizon shall apply the credit to the applicable milestone payment(s) and reflect such application in the invoices it issues therefor. In the event that, following full application by Horizon of the
credit (or remainder thereof) to a milestone payment, a balance of such milestone payment remains due, Horizon will reflect that balance in the applicable invoice therefor, and Mundipharma shall be obligated to pay the balance in accordance with the
terms of the EDA. For clarification, nothing in this letter agreement shall be interpreted to eliminate Mundipharma’s obligation to provide notice to Horizon of its achievement of milestone events. 

(c) Mundipharma agrees to make payment of [...***...] to Horizon within [...***...] of the execution of this letter
agreement, which payment represents the milestone payments due to Horizon for Mundipharma’s achievement of the following milestone events prior to the date of this letter agreement: 

 

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  			
	 [...***...]
	  	 	[...***...]	  
	 [...***...]
	  	 	[...***...]	  
	 [...***...]
	  	 	[...***...]	  
	 [...***...]
	  	 	[...***...]	  
	 [...***...]
	  	 	[...***...]	  

 In addition, Mundipharma agrees to
(i) initiate (first dosing of first patient) prior to [...***...] a study of Product for the treatment of PMR and (ii) subject to the provisions of the EDA, to Launch Product in at least [...***...] of the Second Wave countries
within [...***...] of obtaining Marketing Authorisation therefor in the applicable country. “Launch” with respect to a given country is defined as the date that Mundipharma first purchases commercial supply of Product for such
country. 
 Secondly, Horizon and MMCo wish to clarify section 6.1 of the MSA by adding the following: Notwithstanding anything to the contrary
in section 6.1 of the MSA, the unit price at which Mundipharma purchases Finished Products for a relevant country shall be [...***...] of the Average Net Selling Price of the relevant strength of the Finished Products for such country and
shall only be reduced to [...***...] of the Average Net Selling Price of the relevant strength of the Finished Products for such country as described in Section 6.1 from and after the date that is [...***...] after first Launch of
the Product in that country or, if later the date that is [...***...] after the receipt of payment for the Launch Milestone for such country, but subject always to the minimum price specified in section 6.1 of the MSA. 

  
  

***Confidential Treatment Requested 
 Horizon Pharma AG, Kagenstrasse 17, CH-4153 Reinach, Switzerland 

 

 

  

 Finally, in relation to the Assignment Agreement, the parties agree that the following terms of the
Transfer, License and Supply Agreement dated 21 December 2006, as amended between Merck, Horizon and Horizon GmbH (“TLSA”) for the sale of Product in Germany shall be amended and become effective as of the effective date of the
Assignment Agreement: 
  

	I.	The term of the TLSA shall be 15 (fifteen) years from Launch of the Product in Germany. 

 

	II.	Appendix 2 of the TLSA shall be deleted and replaced with the attached Schedule 1 as Appendix 2. 

 

	III.	The definition of TARGET SALES shall be deleted and replaced with: 

 “TARGET SALES shall mean the target sales as set forth in Appendix 2, such sales of the PRODUCT in the TERRITORY by Mundipharma shall be those reported by Mundipharma as NET SALES per the definition
of NET SALES in the EDA. 
  

	IV.	Article 5.8 of the TLSA shall be deleted, and replaced with the following Article: 

“Should Annual Minimum Sales not be reached in any [...***...] consecutive [...***...] periods (the
first such period to commence upon Launch) during the Term (the “Period of Non-Performance”) due to reasons not attributable to Horizon and/or the third party manufacturer, then Mundipharma shall make up the shortfall during the
[...***...] period following the end of the Period of Non-Performance by paying to Horizon a sum equivalent to [...***...] of the shortfall. If Mundipharma fails to make up the shortfall during the [...***...] period then Horizon
shall have the right to make use of the Marketing Authorisation or Duplicate Authorisation as the case may be to market and sell the Product itself or by a licensee. In such a case, the continuation of this Agreement shall not be subject to any
Annual Minimum Sales.” 
  

	V.	Article 5.9 of the TLSA shall be deleted and replaced with the following Article: 

“For the purposes of Art. 5.6 and 5.7 the sales of the PRODUCT in the TERRITORY by Mundipharma shall be Net Sales per the definition
of NET SALES in the EDA.” 
  

	VI.	Article 7.2 of the TLSA shall only apply for orders for sales of the Product in the calendar year [...***...] and beyond. 

Upon execution of the Assignment Agreement, Horizon and MMCO shall enter into good faith negotiations in order to harmonize the terms of the TLSA with
the terms of the EDA. Such negotiations shall include, but not be limited to: 
  

	 	(a)	The transfer of the Marketing Authorisation in Germany from Horizon to Mundipharma; 

 

	 	(b)	The transfer of pharmacovigilance responsibilities in Germany from Horizon to Mundipharma; 

  
  

***Confidential Treatment Requested 
 Horizon Pharma AG, Kagenstrasse 17, CH-4153 Reinach, Switzerland 

 

 

  

	 	(c)	The review of written or printed material relating to the Product; and 

 

	 	(d)	The establishment of a mechanism for the ordering and supply of the Product in Germany and other territories to the better advantage of all parties.

 Except as expressly amended and supplemented by this letter, the EDA and MSA shall remain in full force and effect in
accordance with their respective terms. Please note your acceptance of the terms of this letter agreement by signing below. This letter agreement may be signed in counterparts, each of which shall be deemed an original, all of which taken together
shall be deemed one instrument. 
 Yours faithfully, 
  

									
	Horizon Pharma AG	 		 	Horizon Pharma GmbH
					
	By:	 	
 

	 		 	By:	 	
 

	Name:	 	Timothy P. Walbert	 		 	Name:	 	Achim Schaeffler
	Title:	 	Chairman, President and CEO	 		 	Title:	 	Managing Director
		 	Managing Director	 		 		 	
				
	Horizon Pharma AG	 		 		 	
					
	By:	 	
 

	 		 		 	
	Name:	 	Robert W. Metz	 		 		 	
	Title:	 	Managing Director	 		 		 	

 Agreed to and accepted as of the date first set forth above: 

 

									
	Mundipharma International Corporation Limited	 		 	Mundipharma Medical Company
					
	By:	 	
 

	 		 	By:	 	
 

	Name:	 	DOUGLAS DOCHERTY	 		 	Name:	 	
	Title:	 	GENERAL MANAGER	 		 	Title:	 	

  
 Horizon
Pharma AG, Kagenstrasse 17, CH-4153 Reinach, Switzerland 

 

 

  

 Schedule 1 

[...***...] 

  
  

***Confidential Treatment Requested 
 Horizon Pharma AG, Kagenstrasse 17, CH-4153 Reinach, Switzerland

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]